Valuation: Madrigal Pharmaceuticals, Inc.

Market Cap 12.16B 10.64B 9.83B 9.17B 17.25B 1,151B 17.57B 118B 45.72B 567B 45.67B 44.65B 1,977B P/E 2026 *
-77x
P/E 2027 * 54.4x
Enterprise Value 11.63B 10.18B 9.4B 8.77B 16.5B 1,101B 16.81B 113B 43.73B 542B 43.68B 42.7B 1,891B EV / Sales 2026 *
7.78x
EV / Sales 2027 * 5.01x
Free-Float
94.32%
Yield 2026 *
-
Yield 2027 * -
1 day+1.83%
1 week+4.69%
Current month+7.98%
1 month+7.98%
3 months+5.14%
6 months-8.91%
Current year-7.79%
1 week 505.05
Extreme 505.05
545.87
1 month 445.2
Extreme 445.2
545.87
Current year 416.21
Extreme 416.21
598.79
1 year 284.02
Extreme 284.0228
615
3 years 119.76
Extreme 119.7604
615
5 years 52.33
Extreme 52.33
615
10 years 6.6
Extreme 6.6
615
Manager TitleAgeSince
Chief Executive Officer 59 07/09/2023
Director of Finance/CFO 62 10/03/2024
Chief Tech/Sci/R&D Officer 58 20/04/2025
Director TitleAgeSince
Chairman 83 21/07/2016
Director/Board Member 73 30/06/2016
Director/Board Member 68 10/08/2016
Date Insider Type Main position Quantity % Market Cap.
06-16Free

Founder

1,220 0.0053%
06-16Free

Director

1,220 0.0053%
06-16
Baker Bros. Advisors LP
FreeCompany 4,880 0.0212%
Change 5-day change 1-year change 3-year change Capi.($)
+1.83%+4.69%+78.54%+143.84% 12.16B
+3.31%+1.93%+69.29%+129.27% 55.78B
-1.32%+16.55%+89.14%+101.41% 55.66B
-1.28%+3.17%-12.81%-13.04% 23.84B
+1.79%+8.13%+7.17%+424.70% 22.7B
+4.45%+8.43%+37.08%-29.19% 16.12B
+0.24%+5.96%+24.59%+186.97% 13.64B
+5.51%+22.37%+171.85%+333.54% 14.8B
-2.37%+7.60%+156.91%+160.12% 11.85B
+1.25%-0.60%+406.90%+126.86% 11.34B
Average +1.34%+5.35%+102.87%+156.45% 23.79B
Weighted average by Cap. +1.20%+4.70%+82.34%+144.13%

Financials

2026 *2027 *
Net sales 1.5B 1.31B 1.21B 1.13B 2.12B 142B 2.16B 14.5B 5.62B 69.76B 5.62B 5.49B 243B 2.21B 1.93B 1.78B 1.66B 3.13B 209B 3.19B 21.39B 8.3B 103B 8.29B 8.1B 359B
Net income -201M -176M -162M -152M -285M -19.02B -291M -1.95B -756M -9.38B -755M -738M -32.69B 308M 269M 249M 232M 437M 29.12B 445M 2.98B 1.16B 14.35B 1.16B 1.13B 50.04B
Net Debt -529M -463M -428M -399M -751M -50.09B -765M -5.13B -1.99B -24.69B -1.99B -1.94B -86.06B -1.09B -958M -885M -826M -1.55B -104B -1.58B -10.61B -4.12B -51.07B -4.11B -4.02B -178B
Logo Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).
Employees
915
Date Price Change Volume
30/06/26 US$536.95 +1.83% 393,458
29/06/26 US$527.28 +2.85% 446,960
26/06/26 US$512.65 -0.22% 2,500,271
25/06/26 US$513.79 +0.79% 362,445
24/06/26 US$509.76 -0.71% 399,805
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
527.28USD
Average target price
678.71USD
Spread / Average Target
+28.72%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MDGL Stock